A novel miniature vagus nerve stimulation (VNS) device known as the MicroRegulator (MR) was effective in reducing signs and symptoms of multidrug refractory rheumatoid arthritis (RA), according to the results of the first-in-human study of the device presented at EULAR 2019.
Vaccination in children undergoing immunosuppressive therapy for rheumatic disease (RD) did not lead to further infections nor cause disease flares, thereby highlighting the safety of both live-attenuated and inactive vaccines in this population, according to data presented at EULAR 2019.
Patients with rheumatoid arthritis (RA) who maintained their disease remission had a significantly reduced risk of clinical and subclinical atherosclerosis, according to the 3-year follow-up data of the GIRRCS* study presented at EULAR 2019.
A treatment combination comprising verinurad and febuxostat could slow chronic kidney disease (CKD) progression by reducing albuminuria and hyperuricaemia in patients with type 2 diabetes (T2D), according to a study presented at EULAR 2019.
Treatment with cyclosporine as maintenance therapy for lupus nephritis appears to lead to faster remission of proteinuria compared with mycophenolate mofetil (MMF) or azathioprine (AZA), although all three drugs are effective in maintaining renal remission in the long run, suggests a study presented at EULAR 2019.
Postmenopausal women who are younger, have higher levels of the bone turnover marker sCTX, and did not receive zoledronate prior to initiating denosumab treatment have an elevated risk of significant bone mineral density (BMD) loss 1 year after denosumab discontinuation, according to results of the ReoLaus* Bone Project presented at EULAR 2019.
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.